Loading
A phase 3 trial testing Cetrelimab in bladder & urothelial cancer, active and no longer recruiting.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder is a phase 3 interventional study registered as NCT04658862, led by Janssen Research & Development, and active but no longer recruiting on the registry. Official title: A Phase 3, Multi-centre, Randomised Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy. Planned enrolment is 518 participants (actual). The study started in 2020-12-07 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.
Shares Cetrelimab, Johnson & Johnson, Bladder & urothelial cancer.
Shares Cetrelimab, Muscle-invasive and advanced bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Cetrelimab, Johnson & Johnson.
Shares Muscle-invasive and advanced bladder cancer, Johnson & Johnson, Bladder & urothelial cancer.
Shares Cetrelimab, Johnson & Johnson.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.